Raymond James Boosts Palvella Therapeutics to Strong Buy Ahead of Key Phase 2 Data

Raymond James upgrades Palvella Therapeutics to Strong Buy with a new $143 price target, citing strong confidence in upcoming Phase 2 TOIVA readout for QTORIN rapamycin.